Sir,

We thank Dr. Mahajan for his comments\[[@CIT1]\] on our paper.\[[@CIT2]\] Our reply to the queries are as follows:

The study was planned to focus the beneficial effects of irbesartan in comparison to insulin and thus the relevance of the study remains clear.Suggestion at 2 is well-taken for future studies.We regret the typing error; please read group III for insulin and group IV for irbesartan.It is a printing error. The original Table ([1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}) submitted to the journal office are reproduced here.

###### 

Effect of irbesartan (20 mg/kg/po) pretreatment on urinary protein excretion in STZ-induced diabetic rats (values are mean ± SEM; n = 10 in each group)

  *Group*              *Urine protein (g/L)*                                                                                                                                             
  -------------------- ----------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------
  I Control            Nil                     Nil                                           Nil                                           Nil                                           Nil
  IISTZ                Nil                     1.0 ± 0.07                                    1.6 ± 0.16                                    1.9 ± 0.16                                    2.1 ± 0.13
  IIIInsulin + STZ     Nil                     Nil                                           Nil                                           Nil                                           Nil
  IVIrbesartan + STZ   Nil                     0.5 ± 0.04[‡](#T000F1){ref-type="table-fn"}   0.8 ± 0.06[‡](#T000F1){ref-type="table-fn"}   0.9 ± 0.08[‡](#T000F1){ref-type="table-fn"}   0.8 ± 0.09[‡](#T000F1){ref-type="table-fn"}

*P* \<0.01 when compared with group II (Student's t-test for unpaired data).

###### 

Effect of irbesartan (20 mg/kg, po) pretreatment on creatinine clearance in STZ-induced diabetic rats (values are mean ± SEM; n = 10 in each group)

  *Group*              *Creatinine clearance (ml/min)*                                                                                                            
  -------------------- --------------------------------- --------------------------------------------- ------------ --------------------------------------------- ----------------------------------------------
  I Control            1.1 ± 0.18                        1.1 ± 0.09                                    1.1 ± 0.04   1.1 ± 0.05                                    1.2 ± 0.06
  IISTZ                0.9 ± 0.07                        1.8 ± 0.16                                    0.9 ± 0.12   0.2 ± 0.11                                    0.1 ± 0.03
  IIIInsulin + STZ     0.9 ± 0.08                        0.9 ± 0.07[‡](#T000F2){ref-type="table-fn"}   0.8 ± 0.06   0.8 ± 0.08[‡](#T000F2){ref-type="table-fn"}   0.7 ± 0.03[‡](#T000F2){ref-type="table-fn"}
  IVIrbesartan + STZ   1.0 ± 0.03                        0.7 ± 0.03[‡](#T000F2){ref-type="table-fn"}   0.6 ± 0.18   0.5 ± 0.15                                    0.4 ± 0.02[‡†](#T000F2){ref-type="table-fn"}

Statistically analyzed by Student's *t*-test (unpaired)

*P* \<0.01 when compared with group II (Student's *t*-test for unpaired data).
